DETAILED NOTES ON HEMGENIX

Range of suitable people: CDEC discussed the uncertainty in the number of individuals with moderately serious to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who are classified as having mild or average disorder could possibly have a critical bleeding

Amount of eligible patients: CDEC mentioned the uncertainty in the amount of sufferers with reasonably significant to critical hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical industry experts consulted by CADTH indicated that some patients who will be categorised as owning moderate or average disorder could possibly have a cr